W R Simons

Summary

Publications

  1. ncbi Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    W Robert Simons
    Global Health Economics and Outcomes Research Inc, Summit, New Jersey 07901, USA
    Clin Ther 25:2972-87. 2003
  2. ncbi The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Manag Care Interface 17:44-9. 2004
  3. ncbi Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study
    W R Simons
    Global Health Economics and Outcomes Research, Inc, Summit, NJ 07901, USA
    Exp Clin Endocrinol Diabetes 114:520-6. 2006
  4. doi An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Pharmacoeconomics 28:765-80. 2010
  5. doi The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data
    W Robert Simons
    Global Health Economics and Outcomes Research Inc, Summit, NJ 07901, USA
    J Occup Environ Med 54:48-55. 2012
  6. ncbi Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Pharmacoeconomics 21:61-74. 2003

Detail Information

Publications6

  1. ncbi Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    W Robert Simons
    Global Health Economics and Outcomes Research Inc, Summit, New Jersey 07901, USA
    Clin Ther 25:2972-87. 2003
    ..1 months vs 5.6 months; P = 0.005). Both treatments were well tolerated, but there were fewer thromboembolic events and a reduced incidence of vaginal bleeding with anastrozole...
  2. ncbi The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Manag Care Interface 17:44-9. 2004
    ..The data suggest that initiation of lamotrigine is associated with reductions in hospital days, a reduction in hospital days of greater than 17 days for some patients, and net cost savings of more than $400 per patient per year...
  3. ncbi Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study
    W R Simons
    Global Health Economics and Outcomes Research, Inc, Summit, NJ 07901, USA
    Exp Clin Endocrinol Diabetes 114:520-6. 2006
    ..The aim of this study was to assess whether earlier transition to insulin in subjects with newly diagnosed type 2 diabetes improves glycaemic control and reduces diabetes-related complications...
  4. doi An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Pharmacoeconomics 28:765-80. 2010
    ....
  5. doi The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data
    W Robert Simons
    Global Health Economics and Outcomes Research Inc, Summit, NJ 07901, USA
    J Occup Environ Med 54:48-55. 2012
    ..Determine the prevalence and costs of rheumatoid arthritis (RA) during three consecutive years: 2004, 2005, and 2006...
  6. ncbi Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan
    W Robert Simons
    Global Health Economics and Outcomes Research, Inc, Summit, New Jersey 07901, USA
    Pharmacoeconomics 21:61-74. 2003
    ..To compare the cost effectiveness of the angiotensin II receptor blockers (ARBs) olmesartan medoxomil, losartan, valsartan and irbesartan for the treatment of hypertension, from the perspective of a US managed care setting...